No Benefit to Adding Chemotherapy in Older Adults With NSCLC
Adding chemotherapy to immunotherapy increased the adverse event burden without improving survival outcomes compared with immunotherapy alone in older adults with NSCLC.
Medscape Medical News
source https://www.medscape.com/viewarticle/no-benefit-adding-chemo-immunotherapy-older-adults-nsclc-2024a10004rp?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/no-benefit-adding-chemo-immunotherapy-older-adults-nsclc-2024a10004rp?src=rss
Comments
Post a Comment